Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02249988
Other study ID # ABX203-002
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received September 19, 2014
Last updated January 23, 2017
Start date December 2014
Est. completion date December 2016

Study information

Verified date September 2015
Source Abivax S.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is an open-label, randomized, comparative, multicenter clinical trial. The purpose of this study is to assess the efficacy of ABX203, a new chronic hepatitis B therapeutic vaccine administered as an adjunct therapy to nucleos(t)ide analogs (NUCs), in maintaining control of Hepatitis B disease after cessation of treatment with NUCs in subjects with HBeAg negative chronic Hepatitis B.


Recruitment information / eligibility

Status Completed
Enrollment 261
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male or female subject between 18 and 65 years of age at the time of randomization.

- Must be HBeAg negative and anti-HBe Abs positive for at least 1 year prior to screening and at screening.

- Has HBV DNA < 40 IU/mL for at least 1 year prior to screening and at screening

- Has both ALT and AST levels = ULN for at least 1 year prior to screening and at screening.

- Must be HBsAg positive at screening.

- Has been treated with NUCs for at least 2 years prior to screening.

- Has not been treated with PEG-IFN or IFN for at least 1 year prior to screening.

- For all females, must have a negative serum pregnancy test at screening. For female of childbearing potential, must have been using adequate contraception and must agree to continue to use it during all study period and for 6 months after completion of the study product administration.

- Has provided written informed consent.

Exclusion Criteria:

- Has elevated blood levels of alpha-fetoprotein (AFP) (> 500 ng/mL).

- Has cirrhosis, defined as

- platelet count < 150,000/mm3, with esophageal varices on imaging and spleen size > 12, or

- liver stiffness of 11 kilopascal [kPa] as measured by elastography using FibroScan® or .an AST to Platelet Ratio Index (APRI) > 2).

- Has hepatocellular carcinoma (HCC) (diagnosed by ultrasonography).

- Has liver decompensation (albumin < 3.5 g/dL and bilirubin =1.3 mg/dL).

- Is Hepatitis C virus (HCV) Ab positive at screening.

- Is Hepatitis delta virus (HDV) Ab positive at screening.

- Is Human Immunodeficiency Virus (HIV) Ab positive at screening.

- Has an immune suppressive disorder or treatment with immunosuppressive drugs.

- Has been treated with corticosteroids within 12 weeks prior to the first administration of study product, with the exception of topical or inhaled corticosteroids.

- Has been treated with rituximab.

- Has other hepatic diseases of different etiology (such as auto-immune hepatitis, toxic hepatitis, Wilson disease, alcoholic or hemochromatosis).

- Has a history of allergic disease or reactions likely to be exacerbated by any component of the study products.

- Has a history of a substance abuse (drug or alcohol) problem within the previous 3 years.

Study Design


Intervention

Drug:
ABX203 therapeutic Hepatitis B vaccine treatment arm


Locations

Country Name City State
Australia Royal Prince Alfred Hospital Camperdown
Australia Monash Medical Centre Clayton Clayton
Australia St Vincent's Hospital Melbourne Fitzroy
Australia Austin Hospital Heidelberg
Australia Liverpool Hospital Liverpool
Australia The Alfred Hospital Melbourne
Australia Royal Melbourne Hospital Parkville
Australia Royal Perth Hospital Perth
Australia Westmead Hospital Westmead
New Zealand Auckland City Hospital Auckland
New Zealand Waikato Hospital Hamilton West
New Zealand Wellington Hospital Wellington

Sponsors (1)

Lead Sponsor Collaborator
Abivax S.A.

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of subjects with viral load < 40 IU/mL at Week 48. Week 48
Secondary Clinical response defined as changes in viral load, liver function, time to relapse Week 48 and Week 96
Secondary Immune response defined as T-cell response by ICS (CD4 and CD8 to HBcAg and HBsAg) Week 48
Secondary Safety assessment will be conducted throughout the study and will include physical examinations, vital signs, clinical laboratory évaluations, and the recording of AEs Participants will be followed for the duration of their study participation up to 96 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Recruiting NCT01360892 - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography N/A